288330 — Bridge Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00- KR₩59bn
- KR₩42bn
- KR₩2m
Annual income statement for Bridge Biotherapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 6,340 | 1,924 | 3,024 | 100 | 2.18 |
| Cost of Revenue | |||||
| Gross Profit | -1,113 | 758 | — | 33.3 | 2.18 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 25,918 | 28,316 | 46,525 | 40,449 | 19,532 |
| Operating Profit | -19,578 | -26,392 | -43,501 | -40,349 | -19,530 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -19,232 | -26,278 | -41,700 | -42,455 | -19,933 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -19,232 | -26,278 | -41,700 | -42,455 | -19,933 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -19,232 | -26,278 | -41,700 | -42,321 | -19,756 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -19,232 | -26,278 | -41,700 | -42,321 | -19,756 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -710 | -947 | -1,479 | -1,449 | -472 |
| Dividends per Share |